Neptune Products to be commercialized by BAYER HealthCare
05 June 2009 - 2:03AM
PR Newswire (US)
LAVAL, QC, June 4 /PRNewswire-FirstCall/ -- Neptune Technologies
& Bioressources Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB)
today announced that it has signed an agreement with Bayer
Healthcare, LLC for the commercialization of Neptune proprietary
products in the United States. "The signing of this agreement with
a partner of the caliber of Bayer supports Neptune's business and
scientific choice to pursue the more demanding and challenging
clinical development path of assessing safety and effectiveness of
its products. As planned, it has been strategic to invest the time
and resources into building a complete portfolio of scientific
data, intellectual property and regulatory approvals which
ultimately allowed the Company to attract the best partner," stated
Dr. Tina Sampalis, Chief Scientific Officer of Neptune. "Neptune's
approach to commercialization consists of rapidly penetrating the
market to generate short-term revenue and growth by partnering with
the right marketer that can create broad consumer awareness
leveraged by our substantial scientific data and that can create
large market share for Neptune. Bayer is among the world's largest
marketers of healthcare products," she added. "Through the
capabilities, reputation and commitment of its partners favoring
growth, Neptune leverages and maximizes value by opening doors for
future product and business development opportunties developed by
Neptune and its pharmaceutical subsidiaries," stated Mr. Henri
Harland, Chief Executive Officer and President of Neptune. "The
parallel stepwise approach of exploring other future products and
project opportunities directed towards pharmaceutical driven
applications is part of the plan," he added. "Under Neptune's
strategic vision, which has been pursued since the beginning of its
operations, the Company has anticipated to penetrate world
nutraceutical and pharmaceutical markets in collaboration with
global international partners. The alliance with Bayer in the
United States represents another important milestone in the
execution of our strategic development plan by the team, so we are
moving in the right direction," he concluded. About Neptune
Technologies & Bioressources Inc. Neptune is an
industry-recognized leader in the innovation, production and
formulation of science-based and clinically-proven novel
phospholipid products for the nutraceutical and pharmaceutical
markets. The Company focuses on growing consumer health markets
including cardiovascular, inflammatory and neurological diseases
driven by consumers taking a more proactive approach to managing
health and preventing disease. The Company carries out clinical
trials to show the therapeutic benefits in various medical
indications and to obtain regulatory approval for health claims.
Neptune is continuously expanding its portfolio of intellectual
property, clinical studies, regulatory approvals and health claims.
Neptune has its products marketed and distributed in over 20
countries worldwide. NASDAQ does not accept responsibility for the
adequacy or accuracy of this press release. Neither TSX Venture
Exchange nor its Regulation Services Provider (as that term is
defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
Statements in this press release that are not statements of
historical or current fact, including statments relating to the
Company's expectation regarding the future performance and
marketability of its products, constitute "forward-looking
statements" within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 and Canadian securities laws. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other unknown factors that could cause the
actual results of the Company to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. In addition to statements which
explicitly describe such risks and uncertainties, readers are urged
to consider statements labeled with the terms "believes," "belief,"
"expects," "intends," "anticipates,"should," "will" or "plans" to
be uncertain and forward-looking. The forward-looking statements
contained herein are also subject generally to other risks and
uncertainties that are described from time to time in the Company's
reports filed with the Securities and Exchange Commission and the
Canadian securities commissions. DATASOURCE: NEPTUNE TECHNOLOGIES
& BIORESSOURCES INC. CONTACT: Toni Rinow, Ph.D., MBA, Corporate
Development & Investor Relations, Neptune Technologies &
Bioressources Inc., (450) 687-2262, ;
http://www.neptunebiotech.com/; Source: Neptune Technologies &
Bioressources Inc.
Copyright